(Total Views: 67)
Posted On: 01/04/2017 8:14:27 AM
Post# of 22865
$BLPH: .70 Jan 4, 2017 Bellerophon Therapeutics Announces FDA Acceptance of Modifications to INOpulse Pulmonary Arterial Hypertension Phase 3 Program
http://www.otcmarkets.com/stock/BLPH/news
http://www.otcmarkets.com/stock/BLPH/news
(0)
(0)
Sojourner here following God, obeying God, and cleaving to Him. The journey is onward.
Scroll down for more posts ▼
